235 related articles for article (PubMed ID: 28653574)
1. Combination of sorafenib and cytokine-induced killer cells in metastatic renal cell carcinoma: a potential regimen.
Yang Y; Lin H; Zhao L; Song Y; Gao Q
Immunotherapy; 2017 Jun; 9(8):629-635. PubMed ID: 28653574
[TBL] [Abstract][Full Text] [Related]
2. Retrospective analysis on the efficacy of sunitinib/sorafenib in combination with dendritic cells-cytokine-induced killer in metastasis renal cell carcinoma after radical nephrectomy.
Mai HX; Mei GH; Zhao FL; Li BT; Tang YY; Zhang B; Xu XJ; Chen LJ
J Cancer Res Ther; 2018 Jun; 14(Supplement):S427-S432. PubMed ID: 29970701
[TBL] [Abstract][Full Text] [Related]
3. Association of myeloid-derived suppressor cells and efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma patients.
Wang Z; Zhang Y; Liu Y; Wang L; Zhao L; Yang T; He C; Song Y; Gao Q
J Immunother; 2014 Jan; 37(1):43-50. PubMed ID: 24316555
[TBL] [Abstract][Full Text] [Related]
4. MDSC-decreasing chemotherapy increases the efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma and pancreatic cancer.
Wang Z; Liu Y; Zhang Y; Shang Y; Gao Q
Oncotarget; 2016 Jan; 7(4):4760-9. PubMed ID: 26716894
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy with cytokine-induced killer cells in metastatic renal cell carcinoma.
Su X; Zhang L; Jin L; Ye J; Guan Z; Chen R; Guo T
Cancer Biother Radiopharm; 2010 Aug; 25(4):465-70. PubMed ID: 20701541
[TBL] [Abstract][Full Text] [Related]
6. Preclinical and clinical studies on cytokine-induced killer cells for the treatment of renal cell carcinoma.
Kim JS; Chung IS; Lim SH; Park Y; Park MJ; Kim JY; Kim YG; Hong JT; Kim Y; Han SB
Arch Pharm Res; 2014 May; 37(5):559-66. PubMed ID: 24691830
[TBL] [Abstract][Full Text] [Related]
7. Targeted treatment for metastatic renal cell carcinoma and immune regulation.
Laschos KA; Papazisis KT; Kontovinis LF; Kalaitzis C; Gianakopoulos S; Kortsaris AH; Touloupidis S
J BUON; 2010; 15(2):235-40. PubMed ID: 20658715
[TBL] [Abstract][Full Text] [Related]
8. High Complete Response Rate in Patients With Metastatic Renal Cell Carcinoma Receiving Autologous Cytokine-Induced Killer Cell Therapy Plus Anti-Programmed Death-1 Agent: A Single-Center Study.
Zhao L; Li T; Song Y; Yang Y; Ma B; Zhang Y; Shang Y; Xu B; Guo J; Qin P; Han L; Fu X; Lin H; Liu L; Ren X; Wang Z; Gao Q
Front Immunol; 2021; 12():779248. PubMed ID: 35058923
[TBL] [Abstract][Full Text] [Related]
9. [Impact of immunotherapy in metastatic kidney cancer in Germany after introduction of new target therapy--results of a telephone survey of the German Society of Immuno- and Targeted Therapy (DGFIT)].
Siebels M; Staehler M; Hegele A; Varga Z; Oberneder R; Doehn C; Heinzer H;
Aktuelle Urol; 2010 Mar; 41(2):122-30. PubMed ID: 19937556
[TBL] [Abstract][Full Text] [Related]
10. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
Eichelberg C; Vervenne WL; De Santis M; Fischer von Weikersthal L; Goebell PJ; Lerchenmüller C; Zimmermann U; Bos MM; Freier W; Schirrmacher-Memmel S; Staehler M; Pahernik S; Los M; Schenck M; Flörcken A; van Arkel C; Hauswald K; Indorf M; Gottstein D; Michel MS
Eur Urol; 2015 Nov; 68(5):837-47. PubMed ID: 25952317
[TBL] [Abstract][Full Text] [Related]
11. Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan.
Eto M; Kawano Y; Hirao Y; Mita K; Arai Y; Tsukamoto T; Hashine K; Matsubara A; Fujioka T; Kimura G; Shinohara N; Tatsugami K; Hinotsu S; Naito S;
BMC Cancer; 2015 Oct; 15():667. PubMed ID: 26452347
[TBL] [Abstract][Full Text] [Related]
12. [Therapeutic efficacy of dendritic cells pulsed by autologous tumor cell lysate in combination with CIK cells on advanced renal cell carcinoma].
Wang H; Feng F; Zhu M; Wang R; Wang X; Wu Y; Zhuang Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2015 Jan; 31(1):67-71. PubMed ID: 25575061
[TBL] [Abstract][Full Text] [Related]
13. Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma.
Cai W; Kong W; Dong B; Zhang J; Chen Y; Xue W; Huang Y; Zhou L; Huang J
Chin J Cancer; 2017 Aug; 36(1):64. PubMed ID: 28789709
[TBL] [Abstract][Full Text] [Related]
14. Outcome and Safety of Sorafenib in Metastatic Renal Cell Carcinoma Dialysis Patients: A Systematic Review.
Leonetti A; Bersanelli M; Castagneto B; Masini C; Di Meglio G; Pellegrino B; Buti S
Clin Genitourin Cancer; 2016 Aug; 14(4):277-83. PubMed ID: 26899142
[TBL] [Abstract][Full Text] [Related]
15. Cytokine-induced killer cells in the treatment of patients with renal cell carcinoma: a pooled meta-analysis.
Wang ZX; Li JL; Cao JX; Liu YS; Li D; Zhang XY; Wang M; Wu M; Xu BL; Liu JL; Wang HB
Immunotherapy; 2014; 6(6):787-95. PubMed ID: 25186607
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib dose escalation in treatment-naïve patients with metastatic renal cell carcinoma: a non-randomised, open-label, Phase 2b study.
Gore ME; Jones RJ; Ravaud A; Kuczyk M; Demkow T; Bearz A; Shapiro J; Strauss UP; Porta C
BJU Int; 2017 Jun; 119(6):846-853. PubMed ID: 27981711
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of metastatic renal cell carcinoma].
Thuret R; Maurin C; Sun M; Perrotte P; Karakiewicz PI
Prog Urol; 2011 Apr; 21(4):233-44. PubMed ID: 21482396
[TBL] [Abstract][Full Text] [Related]
18. T cell-based immunotherapy of metastatic renal cell carcinoma: modest success and future perspective.
Shablak A; Hawkins RE; Rothwell DG; Elkord E
Clin Cancer Res; 2009 Nov; 15(21):6503-10. PubMed ID: 19843660
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.
Sheng X; Chi Z; Cui C; Si L; Li S; Tang B; Mao L; Lian B; Wang X; Yan X; Guo J
Oncotarget; 2016 May; 7(19):27044-54. PubMed ID: 26894858
[TBL] [Abstract][Full Text] [Related]
20. Overview of current and future systemic therapy for metastatic renal cell carcinoma.
Osawa T; Takeuchi A; Kojima T; Shinohara N; Eto M; Nishiyama H
Jpn J Clin Oncol; 2019 May; 49(5):395-403. PubMed ID: 30722031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
